ES2409844T3 - Metodo para el tratamiento y la profilaxis de enfermedades relacionadas con la deposicion de amiloide utilizando IgM - Google Patents

Metodo para el tratamiento y la profilaxis de enfermedades relacionadas con la deposicion de amiloide utilizando IgM Download PDF

Info

Publication number
ES2409844T3
ES2409844T3 ES07756509T ES07756509T ES2409844T3 ES 2409844 T3 ES2409844 T3 ES 2409844T3 ES 07756509 T ES07756509 T ES 07756509T ES 07756509 T ES07756509 T ES 07756509T ES 2409844 T3 ES2409844 T3 ES 2409844T3
Authority
ES
Spain
Prior art keywords
igm
immunoglobulin
preparation
amyloid
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07756509T
Other languages
English (en)
Spanish (es)
Inventor
Jr. Philip Scuderi
Afshin Safavi
Matthew G. Langevin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols Therapeutics LLC
Original Assignee
Grifols Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Therapeutics LLC filed Critical Grifols Therapeutics LLC
Application granted granted Critical
Publication of ES2409844T3 publication Critical patent/ES2409844T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES07756509T 2006-01-30 2007-01-30 Metodo para el tratamiento y la profilaxis de enfermedades relacionadas con la deposicion de amiloide utilizando IgM Active ES2409844T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76342206P 2006-01-30 2006-01-30
US763422P 2006-01-30
PCT/US2007/061269 WO2007106617A2 (en) 2006-01-30 2007-01-30 Method of treatment and prophylaxis of diseases related to amyloid deposition using igm

Publications (1)

Publication Number Publication Date
ES2409844T3 true ES2409844T3 (es) 2013-06-28

Family

ID=38510126

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07756509T Active ES2409844T3 (es) 2006-01-30 2007-01-30 Metodo para el tratamiento y la profilaxis de enfermedades relacionadas con la deposicion de amiloide utilizando IgM

Country Status (7)

Country Link
US (1) US8852585B2 (https=)
EP (1) EP1981540B1 (https=)
JP (2) JP5697847B2 (https=)
ES (1) ES2409844T3 (https=)
PL (1) PL1981540T3 (https=)
PT (1) PT1981540E (https=)
WO (1) WO2007106617A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
RS53174B (sr) 2007-10-05 2014-06-30 Genentech Inc. Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
JP6379113B2 (ja) * 2013-02-26 2018-08-22 バクスアルタ インコーポレイテッド 免疫グロブリンｇの鼻腔内投与による中枢神経系障害の治療
LT2994160T (lt) * 2013-05-06 2019-08-26 Baxalta Incorporated Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
AU2021303496A1 (en) * 2020-07-10 2023-02-02 Grifols Worldwide Operations Limited Method for obtaining a composition comprising human plasma-derived immunoglobulin M

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3927112C1 (https=) * 1989-08-17 1990-10-25 Biotest Pharma Gmbh, 6072 Dreieich, De
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US7473423B2 (en) * 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
AU732508B2 (en) 1996-01-26 2001-04-26 Governing Council Of The University Of Toronto, The Nucleic acids and proteins related to Alzheimer's disease, and uses therefor
EP0835880A1 (de) * 1996-10-14 1998-04-15 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
EP1172378A1 (en) 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
AU2003230391A1 (en) 2002-05-15 2003-12-02 Hazel P. Drew METHOD OF TREATING IMMUNE-MEDIATED DISEASES BY ADMINISTRATION OF IgM
ATE490787T1 (de) * 2003-07-15 2010-12-15 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion

Also Published As

Publication number Publication date
EP1981540B1 (en) 2013-03-20
PL1981540T3 (pl) 2013-08-30
JP2013256529A (ja) 2013-12-26
US20090269359A1 (en) 2009-10-29
EP1981540A2 (en) 2008-10-22
WO2007106617A3 (en) 2008-03-20
US8852585B2 (en) 2014-10-07
JP2009525286A (ja) 2009-07-09
JP5697847B2 (ja) 2015-04-08
WO2007106617A2 (en) 2007-09-20
PT1981540E (pt) 2013-05-07

Similar Documents

Publication Publication Date Title
ES2409844T3 (es) Metodo para el tratamiento y la profilaxis de enfermedades relacionadas con la deposicion de amiloide utilizando IgM
JP7229980B2 (ja) 病理学的タウタンパク質の免疫学的標的化方法
JP7532571B2 (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
US9895429B2 (en) Antibodies that bind amyloid oligomers
US20140314773A1 (en) Compositions and methods for treating alzheimer's disease
ES2389811T3 (es) Oligómeros de amiloide beta para uso en el tratamiento, el alivio o la prevención de la enfermedad de Alzheimer
WO2018031361A2 (en) Combination therapy
JP5709876B2 (ja) 多発性硬化症治療用組成物
KR100774106B1 (ko) 알레르기 질환의 예방 또는 치료를 위한 약학적 조성물,그의 용도 및 알레르기 질환의 예방 또는 치료 방법
US20160303208A1 (en) Method for treating amyloid disease
AU2005211595A1 (en) Peptide fragments of colostrinin and their use
CN116490207A (zh) 基于桦树花粉变应原和苹果变应原的重组多肽
HK1234334A1 (en) Immunological targeting of pathological tau proteins
US20160280742A1 (en) Compositions and Methods for Treating Alzheimer's Disease
BR122024022779A2 (pt) Molécula de ácido nucleico, célula de mamífero, processo para produzir um anticorpo anti-n3pg ab